Home › NDC Lookup › RxCUI directory › RxCUI 248109

Ribavirin 200 MG Oral Tablet — RxCUI 248109

RxNorm drug concept · Semantic clinical drug
RxCUI 248109 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI248109
Official nameRibavirin 200 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)187 prescriptions · 6 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Ribavirin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It depends on the form. Tablets and capsules are used with an interferon medicine to treat chronic hepatitis C. The inhaled form is used in hospitals for severe RSV lung infections...
  • Take them by mouth with food, usually split into two doses a day, as your prescriber directs. Don't open, crush or break the capsules. Keep taking your interferon medicine as presc...
  • How should I take my ribavirin tablets or capsules?
  • Tiredness, headache, fever and chills, nausea, muscle aches, trouble sleeping and mood changes are common. Many of these come partly from the interferon it's paired with. Call us i...
📖 Read our full Ribavirin guide →

🕸️ Concept Web — How Ribavirin 200 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Ribavirin 200 MG Oral Tablet RxCUI 248109

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Ribavirin 9344
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Moderiba 1486192
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Ribavirin Oral Tablet 373774
    • Ribavirin Oral Product 1165449
    • Ribavirin Pill 1165450
    • Ribavirin Oral Tablet [Moderiba] 1486194
    • Moderiba Oral Product 1486195
    • Moderiba Pill 1486196
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Ribavirin 200 MG 332339
    • Ribavirin 200 MG Oral Tablet [Moderiba] 1486200
    • Ribavirin 200 MG [Moderiba] 1486199
  5. Packs 2

    Fixed collections of drugs packaged and sold together, like dose packs.

    • {28 (ribavirin 200 MG Oral Tablet [Moderiba]) / 28 (ribavirin 400 MG Oral Tablet [Moderiba]) } Pack [Moderiba 600 Dose Pack] 1487498
    • {28 (ribavirin 200 MG Oral Tablet) / 28 (ribavirin 400 MG Oral Tablet) } Pack 1298334

Showing up to 8 concepts per family — 15 of 16 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Ribavirin 200 MG SCDC · 332339
  • Ribavirin Oral Tablet SCDF · 373774
  • Ribavirin Oral Product SCDG · 1165449
  • Ribavirin Pill SCDG · 1165450
  • {28 (ribavirin 200 MG Oral Tablet) / 28 (ribavirin 400 MG Oral Tablet) } Pack GPCK · 1298334

Brand-Name Concepts

  • Ribavirin 200 MG Oral Tablet [Moderiba] SBD · 1486200
  • Ribavirin 200 MG [Moderiba] SBDC · 1486199
  • Ribavirin Oral Tablet [Moderiba] SBDF · 1486194
  • Moderiba Oral Product SBDG · 1486195
  • Moderiba Pill SBDG · 1486196
  • Moderiba BN · 1486192
  • {28 (ribavirin 200 MG Oral Tablet [Moderiba]) / 28 (ribavirin 400 MG Oral Tablet [Moderiba]) } Pack [Moderiba 600 Dose Pack] BPCK · 1487498

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 248109 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
65862-0207-05 500 TABLET, FILM COATED in 1 BOTTLE (65862-207-05) Ribavirin Aurobindo Pharma Limited 2009-09-17
65862-0207-68 168 TABLET, FILM COATED in 1 BOTTLE (65862-207-68) Ribavirin Aurobindo Pharma Limited 2009-09-17
Observed labelers: Aurobindo Pharma Limited (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.